REVEAL: A phase I/II, open-label, multicenter, dose escalation and dose expansion study of NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] with or without nivolumab (nivo) in patients (pts) with locally advanced or metastatic solid tumor malignancies

A. Diab; M. Marcondes; M. A. Tagliaferri; U. Hoch; J. Zhang; W. Rubas; S. Kivimae; J. Zalevsky; A. P. Conley; E. Borazanci; S. P. D'Angelo

doi:10.1093/annonc/mdy279.433

REVEAL: A phase I/II, open-label, multicenter, dose escalation and dose expansion study of NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] with or without nivolumab (nivo) in patients (pts) with locally advanced or metastatic solid tumor malignancies

A. Diab, M. Marcondes, M. A. Tagliaferri, U. Hoch, J. Zhang, W. Rubas, S. Kivimae, J. Zalevsky, A. P. Conley, E. Borazanci, S. P. D'Angelo

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	viii146-viii147
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy279.433
State	Published - Oct 1 2018

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdy279.433

Cite this

Diab, A., Marcondes, M., Tagliaferri, M. A., Hoch, U., Zhang, J., Rubas, W., Kivimae, S., Zalevsky, J., Conley, A. P., Borazanci, E., & D'Angelo, S. P. (2018). REVEAL: A phase I/II, open-label, multicenter, dose escalation and dose expansion study of NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] with or without nivolumab (nivo) in patients (pts) with locally advanced or metastatic solid tumor malignancies. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii146-viii147. https://doi.org/10.1093/annonc/mdy279.433

REVEAL: A phase I/II, open-label, multicenter, dose escalation and dose expansion study of NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] with or without nivolumab (nivo) in patients (pts) with locally advanced or metastatic solid tumor malignancies. / Diab, A.; Marcondes, M.; Tagliaferri, M. A. et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.10.2018, p. viii146-viii147.

Research output: Contribution to journal › Article › peer-review

Diab, A, Marcondes, M, Tagliaferri, MA, Hoch, U, Zhang, J, Rubas, W, Kivimae, S, Zalevsky, J, Conley, AP, Borazanci, E & D'Angelo, SP 2018, 'REVEAL: A phase I/II, open-label, multicenter, dose escalation and dose expansion study of NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] with or without nivolumab (nivo) in patients (pts) with locally advanced or metastatic solid tumor malignancies', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii146-viii147. https://doi.org/10.1093/annonc/mdy279.433

Diab A, Marcondes M, Tagliaferri MA, Hoch U, Zhang J, Rubas W et al. REVEAL: A phase I/II, open-label, multicenter, dose escalation and dose expansion study of NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] with or without nivolumab (nivo) in patients (pts) with locally advanced or metastatic solid tumor malignancies. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1;29:viii146-viii147. doi: 10.1093/annonc/mdy279.433

Diab, A. ; Marcondes, M. ; Tagliaferri, M. A. et al. / REVEAL : A phase I/II, open-label, multicenter, dose escalation and dose expansion study of NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] with or without nivolumab (nivo) in patients (pts) with locally advanced or metastatic solid tumor malignancies. In: Annals of oncology : official journal of the European Society for Medical Oncology. 2018 ; Vol. 29. pp. viii146-viii147.

@article{50c2efabe1d34f8c84c1dd2028b8c3b7,

title = "REVEAL: A phase I/II, open-label, multicenter, dose escalation and dose expansion study of NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] with or without nivolumab (nivo) in patients (pts) with locally advanced or metastatic solid tumor malignancies",

author = "A. Diab and M. Marcondes and Tagliaferri, {M. A.} and U. Hoch and J. Zhang and W. Rubas and S. Kivimae and J. Zalevsky and Conley, {A. P.} and E. Borazanci and D'Angelo, {S. P.}",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy279.433",

language = "English (US)",

volume = "29",

pages = "viii146--viii147",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - REVEAL

T2 - A phase I/II, open-label, multicenter, dose escalation and dose expansion study of NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] with or without nivolumab (nivo) in patients (pts) with locally advanced or metastatic solid tumor malignancies

AU - Diab, A.

AU - Marcondes, M.

AU - Tagliaferri, M. A.

AU - Hoch, U.

AU - Zhang, J.

AU - Rubas, W.

AU - Kivimae, S.

AU - Zalevsky, J.

AU - Conley, A. P.

AU - Borazanci, E.

AU - D'Angelo, S. P.

PY - 2018/10/1

Y1 - 2018/10/1

UR - http://www.scopus.com/inward/record.url?scp=85081530544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081530544&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy279.433

DO - 10.1093/annonc/mdy279.433

M3 - Article

C2 - 32136240

SN - 0923-7534

VL - 29

SP - viii146-viii147

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

ER -

REVEAL: A phase I/II, open-label, multicenter, dose escalation and dose expansion study of NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] with or without nivolumab (nivo) in patients (pts) with locally advanced or metastatic solid tumor malignancies

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this